GSK's response to the COVID-19 pandemic

GSK’s response to the COVID-19 pandemic

We are closely monitoring the COVID-19 outbreak. Our Company values guide our response as we support global efforts to tackle the virus, seek to maintain the welfare of our employees and ensure we continue to get our medicines, vaccines and healthcare products to patients and consumers.

Contributing our science

We are contributing our science and expertise where we can have most impact. Our scientists are working with international organisations including the WHO, Coalition for Epidemic Preparedness Innovations (CEPI) and governments worldwide.

One of the most significant contributions we are making is supplying our vaccine adjuvant technology to scientists and organisations working on candidate vaccines and we have started a number of collaborations.

For regular updates on our global response to the pandemic, please visit our global website.

Adapting our ways of working

The welfare of our people is a key priority and we are taking all recommended steps to support and protect them, in line with guidance from public health authorities. In Australia this includes remote working, restricting travel and limiting access to certain sites.

Medicine supply

We are actively managing our global supply chains to minimise potential disruption. We are continuing to monitor the situation closely and will put the needs of patients first at all times. Any impacts to supply will be reported to the Therapeutic Goods Administration and published on our website as per our usual process.

Find out more

GSK global response to COVID-19 pandemic

GSK is closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus. Since the outbreak, we have been actively exploring ways to help, with our science and expertise, alongside protecting the health and wellbeing of our people and managing our global supply chains to support patients and consumers who depend on our products.